-
Mashup Score: 0
Ripretinib now has 2 breakthrough therapy designations from the FDA and has been added to the NCCN guidelines for gastrointestinal stromal tumor.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0NCCN Guidelines Support Sodium Thiosulfate to Mitigate Cisplatin-Induced Hearing Loss in Pediatric Patients With Cancer - 1 year(s) ago
According to Fennec Pharmaceuticals, the National Comprehensive Cancer Network is updating it guidelines to recommend injections of sodium thiosulfate to reduce the risk of ototoxicity in pediatric patients receiving cisplatin.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
NCCN Guidelines Support Sodium Thiosulfate to Mitigate Cisplatin-Induced Hearing Loss in Pediatric Patients With Cancer #ototoxicity #pediatriconcology #nursing #oncology #NCCN Link: https://t.co/nYupUwpIuO
-
-
Mashup Score: 0NCCN Guidelines Add Neratinib for Patients With Breast Cancer - 1 year(s) ago
Positive data from 2 phase 2 studies, SUMMIT and MutHER, have led to the addition of neratinib as a monotherapy or in combination to the National Comprehensive Cancer Network Guidelines for patients with breast cancer.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Neratinib has been added to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for patients with breast cancer. #bcsm #NCCN https://t.co/4hnWKDaAb2
-
-
Mashup Score: 0Flaig Discusses NCCN Guidelines in Bladder Cancer - 1 year(s) ago
Thomas Flaig, MD, discusses some of the updated and current NCCN guidelines for patients with bladder cancer.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Thomas Flaig, MD, discusses some of the updated and current @NCCN guidelines for patients with bladder cancer. #NCCN #blcsm | @CUCancerCenter https://t.co/81Up58NVS6
-
-
Mashup Score: 0
In an interview with Targeted Oncology, Thomas Flaig, MD, further discussed the updates to the 2022 NCCN guidelines for patients with bladder cancer and explained how the field has evolved over the past few years.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Thomas Flaig, MD explained recent updates to the 2022 #NCCN guidelines for patients with #bladdercancer and explained how the field has evolved over the past few years. #blcsm | @NCCN @CUCancerCenter https://t.co/2AXPnOC8Os https://t.co/srhU2SQnK4
-
-
Mashup Score: 0Wolters Kluwer Health - 1 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#NCCN Highlights New Treatment Advances in #BloodCancer: https://t.co/Hjbn0EhUbD #HemOnc https://t.co/dVOc1FmoXN
-
-
Mashup Score: 1
During a live virtual event, Zofia Piotrowska, MD, MHS, discussed the National Comprehensive Cancer Network guidelines for molecular testing for a patient with advanced non–small cell lung cancer, and how to approach a patient who is found to have an EGFR exon 20 insertion. This is the first of 2 articles based on this event.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
During a live virtual event, Zofia Piotrowska, MD, MHS, discussed the #NCCN guidelines for molecular testing for a patient with advanced non–small cell lung cancer, and how to approach a patient who is found to have an EGFR exon 20 insertion. #nsclc #lcsm https://t.co/E2xMm1Bte0
-
-
Mashup Score: 0
Nizar Tannir, MD, provides an overview of the method of risk stratification for advanced RCC and the NCCN Guidelines for treatment based on risk group.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Nizar Tannir, MD, provides an overview of the method of risk stratification for advanced #RCC and the #NCCN Guidelines for treatment based on risk group. #kcsm @MDAndersonNews @ClevelandClinic @fredhutch https://t.co/MGanI5GDDx
-
-
Mashup Score: 7What’s new in the NCCN’s guidelines for prostate cancer? - 2 year(s) ago
“What was published in May of 2022 was version 4 of the 2022 guidelines,” says Edward M. Schaeffer, MD, PhD.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
What’s new in the NCCN’s guidelines for prostate cancer? https://t.co/DqOvyn7uT6 #urology #urologist #NCCN #prostatecancer @NM_Urology
-
-
Mashup Score: 1Dr. Schaeffer discusses NCCN guideline development process - 2 year(s) ago
“I think most panelists are happy to participate in those meetings, because generally speaking, those ad hoc meetings are done because there’s a new advance in the field,” says Edward M. Schaeffer, MD, PhD.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
Dr. Schaeffer discusses NCCN guideline development process https://t.co/rOFotR7CLX #urology #urologist #NCCN @NM_Urology
-
The #FDA has granted 2 BTDs to #ripretinib for #GIST and the agent has been added to the #NCCN Guidelines. #sarcoma | @DanaFarber https://t.co/eikZsZHMbY